Weight in Parkinson's Disease: Phenotypical Significance

Area of Science:

• Neurology
• Metabolic Medicine

Background:

• Body weight is a critical nonmotor feature in Parkinson's disease (PD), with complex homeostatic derangements.
• Both low and high body weight are implicated as risk factors, though most PD patients exhibit lower weight or experience loss during disease progression.

Purpose of the Study:

• To explore the relationship between body weight changes and clinical parameters in Parkinson's disease.
• To identify phenotypes associated with weight fluctuations and their impact on disease progression and complications.

Main Methods:

• Analysis of clinical parameters associated with weight changes in PD patients.
• Assessment of olfactory function as a predictor of weight loss.
• Correlation of body weight, levodopa dosage, and dyskinesia risk.

Main Results:

• Low body weight and weight loss negatively impact PD severity, quality of life, and mortality.
• Olfactory impairment, particularly severe loss (anosmia), is linked to higher risk of weight loss.
• Higher body weight may offer protection against levodopa-induced dyskinesia.

Conclusions:

• Identifying PD patients by phenotypes such as "Park-olfaction-weight" and "olfaction-weight-dyskinesia" can inform strategies to prevent weight loss and manage complications.
• Weight monitoring and a weight-oriented approach are crucial for improving PD patient outcomes.
• Body weight changes may serve as a surrogate marker for disease progression and a target for neuroprotection research.